Elicio Therapeutics Hits New 52-Week High of $12.61

Elicio Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 12.61 on September 17, 2025. This achievement marks a notable increase from its 52-week low of USD 4.05, reflecting a robust performance over the past year.
In the last year, Elicio Therapeutics has demonstrated a remarkable performance of 43.75%, significantly outperforming the S&P 500, which recorded a gain of 17.28% during the same period. The company's market capitalization stands at USD 191 million, indicating its position within the Pharmaceuticals & Biotechnology industry.

Despite being a loss-making entity, Elicio's stock performance highlights its potential within a competitive market. The company's financial metrics, including a debt-to-equity ratio of -6.43 and a return on equity of -2,404.47%, provide insight into its financial structure. However, the absence of a dividend yield and a high price-to-book ratio of 104.32 suggest a focus on growth rather than immediate returns. Overall, Elicio Therapeutics' recent stock activity underscores its evolving market presence.